S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/BVF Partners/Q4 2020

BVF Partners

Period: Q4 2020 Β· Filed: 2021-02-12
View on SEC EDGAR β†—
AUM
$2.54B
Total portfolio value
Positions
68
Reported securities
Top Holding
OLMA
12.6% $320.3M
QoQ Changes
+8 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2021-02-12) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
OLMAOLEMA PHARMACEUTICALS INC$320.3M12.60%$48.08$12.64-73.7%
12.6%
XOMAXOMA CORP DEL$184.6M7.26%$44.13$43.00-2.6%
7.3%
KYMRKYMERA THERAPEUTICS INC$163.1M6.42%$62.00$113.51+83.1%
6.4%
RLAYRELAY THERAPEUTICS INC$127.7M5.02%$41.56$18.65-55.1%
5.0%
RVMDREVOLUTION MEDICINES INC$109.6M4.31%$39.59$189.24+378.0%
4.3%
RPTXREPARE THERAPEUTICS INC$102.0M4.01%β€”β€”
4.0%
MRUSMERUS N V$101.8M4.00%β€”β€”
4.0%
CYTKCYTOKINETICS INC$101.4M3.99%$20.78$86.49+316.2%
4.0%
PTGXPROTAGONIST THERAPEUTICS INC$86.2M3.39%$20.16$131.62+552.9%
3.4%
IONSIONIS PHARMACEUTICALS INC$77.2M3.03%$56.54$81.80+44.7%
3.0%
RCUSARCUS BIOSCIENCES INC$71.5M2.81%$25.96$30.33+16.8%
2.8%
XNCRXENCOR INC$55.2M2.17%$43.63$15.00-65.6%
2.2%
XENEXENON PHARMACEUTICALS INC$53.8M2.12%$15.38$60.96+296.4%
2.1%
AMRNXXXXAMARIN CORP PLC$52.6M2.07%β€”β€”
2.1%
ACIUAC IMMUNE SA$50.8M2.00%$5.17$2.51-51.5%
2.0%
ALXOALX ONCOLOGY HLDGS INC$46.6M1.83%$86.20$2.07-97.6%
1.8%
FDMT4D MOLECULAR THERAPEUTICS IN$45.9M1.80%$41.45$13.00-68.6%
1.8%
IDYAIDEAYA BIOSCIENCES INC$45.2M1.78%$14.00$37.65+168.9%
1.8%
EPIXESSA PHARMA INC$44.2M1.74%β€”β€”
1.7%
SPROSPERO THERAPEUTICS INC$43.5M1.71%$19.39$2.20-88.7%
1.7%
KURAKURA ONCOLOGY INC$40.7M1.60%$32.66$11.10-66.0%
1.6%
STROSUTRO BIOPHARMA INC$40.3M1.58%$217.10$30.43-86.0%
1.6%
LXRXLEXICON PHARMACEUTICALS INC$37.5M1.47%$3.42$2.32-32.2%
1.5%
INFIQINFINITY PHARMACEUTICALS INC$36.9M1.45%$2.12$0.00
1.4%
CTMXCYTOMX THERAPEUTICS INC$36.5M1.44%$6.55$3.82-41.7%
1.4%
GLYCGLYCOMIMETICS INC$35.9M1.41%β€”β€”
1.4%
FBRXFORTE BIOSCIENCES INC$26.2M1.03%$910.25$20.92-97.7%
1.0%
CALTCALLIDITAS THERAPEUTICS AB$25.5M1.00%β€”β€”
1.0%
VSTMXXXXVERASTEM INC$23.8M0.94%β€”β€”
0.9%
IMVTIMMUNOVANT INC$23.8M0.93%$46.19$38.79-16.0%
0.9%

Quarter-on-Quarter Activity

Q4 2020 vs. Q3 2020

New Positions (8)

TickerIssuerNotionalSince Filing
OLMAOLEMA PHARMACEUTICALS INC$320.3M-73.7%
FDMT4D MOLECULAR THERAPEUTICS IN$45.9M-68.6%
LXRXLEXICON PHARMACEUTICALS INC$37.5M-32.2%
COGTCOGENT BIOSCIENCES INC$17.2M
NVUSNOVUS THERAPEUTICS INC$11.8M
GRTSQGRITSTONE ONCOLOGY INC$10.6M
EUCRUEUCRATES BIOMEDICAL ACQU COR$5.3M
FLACUFRAZIER LIFESCIENCES ACQU CO$5.2M

Exited Positions (8)

TickerIssuerNotional
CLDXCELLDEX THERAPEUTICS INC NEW$45.5M
REPLREPLIMUNE GROUP INC$39.0M
ANABANAPTYSBIO INC$18.1M
EVLOEVELO BIOSCIENCES INC$6.8M
NVUSNOVUS THERAPEUTICS INC$3.3M
BLRXBIOLINERX LTD$2.8M
SBPHSPRING BK PHARMACEUTICALS IN$1.3M
EXELEXELIXIS INC$0.4M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
AMRNXXXXAMARIN CORP PLC$48.0M+878.3%
IONSIONIS PHARMACEUTICALS INC$42.3M+85.6%+44.7%
PTGXPROTAGONIST THERAPEUTICS INC$39.8M+80.1%+552.9%
SPROSPERO THERAPEUTICS INC$28.5M+66.9%-88.7%
CTMXCYTOMX THERAPEUTICS INC$12.8M+56.7%-41.7%
CYTKCYTOKINETICS INC$29.4M+46.8%+316.2%
RVMDREVOLUTION MEDICINES INC$36.5M+31.7%+378.0%
GLYCGLYCOMIMETICS INC$13.7M+31.7%

Trimmed (8)

TickerIssuerNotionalShares Ξ”Since Filing
SWTXSPRINGWORKS THERAPEUTICS INC$-97.9M-100.0%
PANAUPANACEA ACQUISITION CORP$-9.5M-98.8%
FPRXFIVE PRIME THERAPEUTICS INC$-20.0M-87.0%
CRISCURIS INC$0.9M-82.8%
SNDXSYNDAX PHARMACEUTICALS INC$-16.9M-64.4%
ARGXARGENX SE$-26.1M-63.2%
RNACSELECTA BIOSCIENCES INC$-11.0M-60.9%
IMVTIMMUNOVANT INC$-18.4M-57.1%-16.0%
← Back to Hedge Funds